Objective: Human T cell lymphotropic virus 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a chronic, progressive, neurological disease. Chronic activation of CD8 + T cells, as evidenced by increased spontaneous lymphoproliferation and HTLV-1-specific cytotoxic T cells, has been demonstrated in HAM/TSP patients. Since IL-2 and IL-15 stimulate memory CD8 + T cell activity, these cytokines have been implicated in the immunopathogenesis of HAM/TSP. In this phase I trial, we evaluated the safety, pharmacokinetics, and ability of Hu-Mikb1, a humanized monoclonal antibody directed toward the IL-2/IL-15 receptor b-chain (IL-2/IL-15Rb: CD122), to saturate CD122 and regulate abnormal immune responses in patients with HAM/TSP by inhibition of IL-15 action. Methods: Hu-Mikb1 was administered intravenously at doses of 0.5 mg/kg, 1.0 mg/kg, or 1.5 mg/kg in a total of nine HAM/TSP patients. Five doses of Hu-Mikb1 were administered at 3-week intervals. The clinical response was evaluated using standardized scales. Viral and immunologic outcome measures were examined including HTLV-1 proviral load, T cell phenotypic analysis and spontaneous lymphoproliferation in HAM/TSP patients. Results: There was no significant toxicity associated with Hu-Mikb1 administration in HAM/TSP patients. Saturation of CD122 by Hu-Mikb1 was achieved in five out of nine HAM/TSP patients. Administration of Hu-Mikb1 was associated with inhibition of aberrant CD8 + T cell function including spontaneous lymphoproliferation and degranulation and IFN-c expression, especially in HAM/TSP patients that achieved CD122 saturation. Interpretation: The treatment with Hu-Mikb1 had a number of immunological effects on HAM/TSP patients although no clinical efficacy was observed. We also did not see any dose-related toxicity.
Introduction
Human T cell lymphotropic virus 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a chronic, progressive, neurological disease. 1, 2 Currently, no therapy has been shown to significantly modify the longterm disability associated with HAM/TSP. 3 HTLV-1 proviral DNA load (PVL) is significantly elevated in the peripheral blood and cerebrospinal fluid (CSF) of HAM/ TSP patients and is strongly correlated with disease This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
pathogenesis. 4, 5 HAM/TSP is characterized by perivascular inflammatory infiltrates, predominantly CD8 + T cells, in chronic inflammatory lesions of the central nervous system, affecting the spinal cord in particular patients. 6, 7 Notably, increased numbers of memory and/or effector CD8 + T cells and HTLV-1 Tax-specific cytotoxic CD8 + T cells were found in the peripheral blood, CSF and spinal cord of HAM/TSP patients. [8] [9] [10] Chronic immune activation associated with HTLV-1 infection has been suggested to underlie the pathogenesis of this disorder.
HTLV-1 expresses a transcriptional trans-activator protein, Tax, which induces the expression of a number of the common c chain family of cytokines and their receptors, such as IL-2/IL-2R and IL-15/IL-15R. [11] [12] [13] Both cytokines induce the proliferation and increase the cytolytic activity of NK and CD8 + T cells, and the receptors for IL-2 and IL-15 share the IL-2Rb and c chains. 13 IL-2 and IL-15 could also regulate the expression of inhibitory receptors, such as CD244 and Tim-3, leading to regulation of CD8 + T cell differentiation and exhaustion. 14 In particular, IL-15 is critical for the development of NK cells and antigen-specific memory CD8
+ T cells and is well characterized for its role in maintaining memory pools of CD8 + T cells. 13 HAM/TSP patients showed high frequency of CD4 + CD25(IL-2Ra ) + T cells which contain high HTLV-1 PVL, express HTLV-1 tax mRNA and induce various cytokines. 15, 16 The treatment of HAM/TSP patients with anti-Tac, a humanized monoclonal antibody to the IL-2Ra , demonstrated several inhibitory effects on spontaneous lymphoproliferation and HTLV-1 PVL in PBMCs. 17 In addition to IL-2, IL-15 has been suggested to be involved in pathogenesis of HAM/TSP, potentially through upregulation of IL-15. [18] [19] [20] Since increased expressions of these critical immune mediators may directly contribute to cell activation and proliferation observed in HAM/TSP patients, IL-15/IL-15R autocrine loop might be a critical therapeutic target for HAM/TSP.
Hu-Mikb1 is a humanized monoclonal antibody to the b chain shared by the IL-2 and IL-15 receptors (IL-2/IL15Rb; CD122). Hu-Mikb1 was shown to block IL-15 transpresentation and IL-15-induced cell proliferation and was evaluated in a phase I clinical trial in patients with T cell large granular lymphocyte leukemia. 21 Previous ex vivo studies demonstrated that Hu-Mikb1 inhibited abnormal T cell proliferation and HTLV-1-specific cellular immune responses of HAM/TSP patients, 19, 20, 22 suggesting that Hu-Mikb1 might contribute to blocking IL-15 action in HAM/TSP patients. Based on its effects, we hypothesized that the administration of Hu-Mikb1 in HAM/TSP patients would lead to inhibition of abnormal T cell functions. HAM/TSP patients were intravenously treated with Hu-Mikb1 at doses of 0.5 mg/kg (group 1), 1.0 mg/kg (group 2), or 1.5 mg/kg (group 3) based on the previous clinical trials. 21, 23 The primary goals of this phase I trial were to evaluate the safety, pharmacokinetics, and ability to saturate the IL-2/IL-15Rb and regulate immune responses in HAM/TSP patients following the administration of Hu-Mikb1.
Methods

Patients and treatment plan
Nine patients with clinically defined HAM/TSP by the WHO criteria 24 were enrolled into the clinical trial of Hu-Mikb1 in HAM/TSP (NCT00076843). Hu-Mikb1 was administered intravenously at doses of 0.5 mg/kg (group 1), 1.0 mg/kg (group 2), or 1.5 mg/kg (group 3). Each patient received five doses of Hu-Mikb1, were administered at 3-week intervals. PBMCs were isolated and cryopreserved in liquid nitrogen until use. CSF was obtained by lumbar puncture and the cells were collected by centrifugation of CSF samples. The study protocol (04-N-0071) was reviewed and approved by the National Institute of Neurological Disorders and the Stroke Institutional Review Board. Prior to study inclusion, written informed consent was obtained from all the participants in accordance with the Declaration of Helsinki. Details on this clinical trial are recorded at clinicaltrials.gov (NCT00076843).
Flow cytometry
For analysis of peripheral blood lymphocyte populations, EDTA-treated whole blood of HAM/TSP patients and healthy volunteers (HVs) were stained with CD3, CD4,  CD8, CD14, CD19, CD25, CD27, CD45, CD45RA,  CD45RO, CD56, CD95, CD122 (clone Mikb2 and  Mikb3) , CD197 (CCR7), CD244 (all from BD Biosciences), CD279 (PD-1; BioLegend), and Tim-3 (R&D Biosystems). Mikb1 and Mikb3 identified noncompeting epitopes on the IL-2/IL-15Rb, but Mikb1 and Mikb2 appeared to recognize the same epitope or very closely related epitopes on the b chain. 21, 25 Tax 11-19/HLA-A201 tetramer was provided by National Institute of Allergy and Infectious Diseases Major Histocompatibility Complex Tetramer Core Facility. CMV pp65/HLA-A201 tetramer (Beckman Coulter) was used as control. For detection of phosphorylated STAT5 (pSTAT5), EDTAtreated whole blood were incubated for 15 min at 37°C and lysed with BD Phosflow TM Lyse/Fix buffer (BD Biosciences). After washing and permeabilization with cold 90% methanol on ice for 30 min, the cells were stained with antibodies for CD3, CD4, CD8, and pSTAT5 (all from BD Biosciences). CD107a mobilization assay was performed as previously described. 20 All flow cytometric analyses were performed using a FACSCalibur or LSR II (both from BD Biosciences). The data were analyzed using FlowJo 10.2 software (FlowJo LLC).
Lymphoproliferation assay
Lymphoproliferation assay was performed as previously described. 26 PBMCs were cultured in triplicate and pulsed after 3 to 5 days of culture with 1 lCi [ 3 H] thymidine. The average cpm from each of the wells was plotted.
HTLV-1 PVL
HTLV-1 PVL was measured using ddPCR (Bio-Rad) as previously described. 27 Primers and probe specific to HTLV-1 tax and human ribonuclease P protein subunit 30 were used.
Statistics
The Mann-Whitney test was used to compare: pSTAT5, PD-1, CD244 and Tscm cells between HVs and HAM/TSP patients. Paired t test was used to compare: pSTAT5, PD-1, CD244, and Tscm cells at pretreatment and at post-HuMikb1 treatment of HAM/TSP patients. All statistical analyses were performed using Prism (GraphPad software).
Results
Patients characteristics
Nine HAM/TSP patients were enrolled into this phase I clinical trial of Hu-Mikb1. All had a slowly progressive course of neurologic disease. The demographic characteristics of the study population are summarized in Table 1 . Mean age of the study population was 52.8 years. The majority of patients were female and were predominantly African American. Mean disease duration of the study population was 11.6 years.
Safety and clinical response of Hu-Mikb1
Adverse events in HAM/TSP patients during the trial are summarized in Table 2 . Two subjects (dosed at 0.5 mg/ kg) developed deep vein thrombosis (DVT) of the lower extremities after the protocol-specified observation period (at three and three and one-half months following the final administration of Hu-Mikb1). One subject (dosed at 1.0mg/kg) developed DVT around 2 months following the last administration of Hu-Mikb1. This was asymptomatic and was diagnosed by Doppler of the lower extremities as required per protocol. While this was reported as possibly related to the research, prolonged immobilization secondary to the underlying myelopathy was identified as a major risk factor for DVT in both subjects and was likely contributory. An independent data safety monitoring board concurred with these observations and recommended prophylactic anticoagulation therapy as well as excluding patients that were nonambulatory.
The clinical responses were evaluated using standardized scales including expanded disability status scale (EDSS), Scripps neurologic rating scale (SNRS), Timed 25-Foot Walk (T25-FW), ambulation index (AI), and Insituto de Pesquisa Clinica Evandro Chagas (IPEC). Clinical effects of Hu-Mikb1 in the study population are summarized in Table 3 . For the all doses, there were no changes in the rate of clinical progression during the study period and no serious infusion toxicities. One patient (HAM#5, dosed at 1.0mg/kg) had a subjective improvement in bladder function (nocturia) at week 3 that was sustained throughout the study.
Saturation of CD122 on NK cells of HAM/TSP patients
NK cells express high frequency of CD122. In the nine HAM/TSP patients, CD122 was highly expressed on NK cells (Mikb2: 81. 4 (Fig. 1B) . The five patients also showed more than 90% saturation of CD122 on CD56 + NK cells (Fig. 1C) . These results demonstrated that Hu-Mikb1 could saturate IL-2/IL15Rb in HAM/TSP patients, which might be in a dosedependent manner. Consistent saturation of CD122 on CD56 + NK cells were achieved in HAM#5, #6, and #8
during the Hu-Mikb1 treatment phase of the trial and were maintained up to 3 weeks after the final dose but lost by 6 weeks after the final dose (Fig. 1D , left graph).
HAM#1, #4, and #9 demonstrated delayed or partial saturation of CD122 on CD56 + NK cells during the HuMikb1 treatment period (Fig. 1D, center graph) . In the other patients (HAM#2, #3, and #7), any consistent saturation was not observed during the Hu-Mikb1 treatment phase of the trial (Fig. 1D, right Fig. 2A) . Group analysis of frequencies of Mikb2 + CD8 + T cells in HAM/TSP patients demonstrated that 25% of group 1 (one of four patients), 66.7% of group 2 (two of three patients) and 100% of group 3 patients (two of two patients) showed more than 90% saturation of CD122 on CD8 + T cells at week 12 of HuMikb1 treatment ( Fig. 2B and C) . Time course analysis indicated that HAM#1, #5, #6, and #8 sustained the consistent saturation of CD122 on CD8 + T cells during the Hu-Mikb1 treatment period followed by gradual loss of CD122 saturation on CD8 + T cells during the posttreatment period (Fig. 2D, left graph) . In the other patients (HAM#2, #3, #4, #7, and #9), CD122 was partially or transiently saturated on CD8 + T cells (Fig. 2D, right graph). Notably, HAM/TSP patients without significant saturation of CD122 on NK cells also showed a partial saturation of CD122 on CD8 + T cells after Hu-Mikb1 administration (HAM#2 and #3). These results demonstrated that Hu-Mikb1 could also saturate IL-2/IL-15Rb on CD8 + T cells of HAM/TSP patients.
Relatively high frequency of HTLV-1 Tax-specific CD8 + T cells are detected in the peripheral blood of HAM/TSP patients. 10 One HAM/TSP patient (HAM#3, Group 1) expressed the HLA-A201 allele, allowing for the detection of HTLV-1-specific and CMV-specific CD8 + T cells was able to detect in the peripheral blood using Tax11-19/HLA-A201 and CMV pp65/HLA-A201 tetramers, respectively (Fig. 2E ). This allowed for reliable monitoring of changes to the frequencies of HTLV-1- Tax-specific and 1.88% of CD8 + T cells were CMV pp65-specific. The frequencies of both virus-specific CD8 + T cells did not change significantly over the treatment period (Fig. 2F) . Of note, the patient (HAM#3) showed only a partial saturation of CD122 on CD8 + T cells (Fig. 2D, right graph) .
Inhibitory effects of Hu-Mikb1 on T cell function of HAM/TSP patients
Spontaneous lymphoproliferation is a well-established measure of ex vivo T cell activation for HTLV-1-infected subjects. 28 Partial inhibition of spontaneous lymphoproliferation was detected in the HAM/TSP patients at week 9 and/or week 15 of Hu-Mikb1 treatment (Fig. 3A) . In particular, patients that achieved full saturation of CD122 during the Hu-Mikb1 treatment period (e.g., HAM#6, #8, and #9) demonstrated greater than 50% inhibition of spontaneous proliferation at week 9 or week 15 of HuMikb1 treatment (Fig. 3A) . Spontaneous degranulation and IFN-c expression has been reported to be increased in CD8 + T cells of HAM/ TSP patients and inhibited by Hu-Mikb1 in ex vivo PBMC culture of HAM/TSP patients. 20 HAM/TSP patients in group 3 showed 57.0-64.6% inhibition of spontaneous degranulation and IFN-c expression in CD8 + T cells at week 9 of Hu-Mikb1 treatment (Fig. 3B ) and varying degrees of inhibition was sustained over the treatment period (Fig. 3C) . HAM/TSP patients in the lower dose groups (group 1 and 2) showed less inhibitory effects of Hu-Mikb1 on spontaneous degranulation and IFN-c expression in CD8 + T cells (Fig. 3B) . These results demonstrated that the administration of Hu-Mikb1 led to inhibition of CD8 + T cell function in the HAM/TSP patients in a partly dose dependent manner. It has been reported that PBMCs from HAM/TSP patients showed increased STAT5 activation, as indicated by STAT5 phosphorylation, in short-term (20 h) culture, which was partially inhibited by Hu-Mikb1. 22 In the current study, we examined pSTAT5 in CD4 + and CD8 + T cells of HVs and HAM/TSP patients using fresh whole blood. As shown in Figure 3D , HAM/TSP patients showed significantly increased pSTAT5 in both CD4 + and CD8 + T cells of peripheral blood compared to HV. When we compared the frequencies of pSTAT5 in CD4 + and CD8 + T cells at pretreatment and at week 9 of Hu-Mikb1 treatment in the higher dose groups (group 2 and 3), HAM/TSP patients showed significant decreases of pSTAT5 in CD4 + T cells of peripheral blood (Fig. 3E, left) following Hu-Mikb1 treatment. In CD8 + T cells, pSTAT5
was decreased after Hu-Mikb1 treatment and approached significance (Fig. 3E, right) .
Alternative effects of Hu-Mikb1 on CD8 + T cell subsets of HAM/TSP patients
Given the inhibitory effects of Hu-Mikb1 on T cell function, we asked whether Hu-Mikb1 administration also modulated additional aspects of CD8 + T cell function. In HAM/TSP patients, alternative expressions of various inhibitory receptors, such as PD-1, CD244, and Tim-3, have been demonstrated on CD8 + T cells. [29] [30] [31] [32] To determine whether the cells expressing the inhibitory receptors (PD-1, CD244, and Tim-3) were affected by Hu-Mikb1 administration, we examined the frequencies of PD-1 
CD8
+ T cells (HAM#6 and 9; Fig 4B and C) .
A new subset of human memory CD8 + T cells, stem cell-like memory T cells (Tscm) cells, has been reported to be identified based on expression of CD122 and CD95 in na€ ıve phenotypes and constituted a long-lived, self-renewing lymphocyte population essential for the maintenance of functional immunity, which might be associated with infectious diseases and autoimmune diseases. [33] [34] [35] Compared to HVs, the frequency of Tscm was significantly increased in HAM/TSP patients (Fig. 4D) .
Although there was no significant difference of Tscm frequency in CD8 + T cells of HAM/TSP patients at pretreatment and at week 12 of Hu-Mikb1 treatment by group analysis, two HAM/TSP patients (HAM#6 and #8) showed decrease in Tscm in CD8 + T cells during HuMikb1 treatment (Fig. 4D) .
HTLV-1 PVL in HAM/TSP patient during HuMikb1 trial
We also analyzed HTLV-1 PVL in PBMCs of HAM/TSP patients during the trial. HTLV-1 PVL of the HAM/TSP patients was detected at 6.63-43.77% in PBMC before the treatment and the reduction of HTLV-1 PVL at week 12 of Hu-Mikb1 treatment was 0-44.8% in PBMC of the patients (Fig. 4E, left graph) . Of nine HAM/TSP patients, we were able to analyze HTLV-1 PVL in CSF cells of four HAM/TSP patients (HAM#5, #6, #8, and #9) at pretreatment and at week 12 of Hu-Mikb1 treatment (Fig. 4E , right graph). HTLV-1 PVL was detected at 37.69-72.33% in the CSF cells at pretreatment which was much higher than the PVL in the PBMCs of each patient. At week 12 of Hu-Mikb1 treatment, HTLV-1 PVL in the CSF cells was trending to decrease (5.2-22.4% reduction) but remained higher than that in the PBMCs of the patients (Fig. 4E, right graph) . These results suggested that HuMikb1 did not directly alter HTLV-1 PVL in HAM/TSP patients.
Discussion
Activation and dysregulation of CD8 + T cells have been implicated in disease progression and pathogenesis of HAM/TSP. In this study, treatment with a humanized monoclonal antibody to the IL-2/IL-15Rb, Hu-Mikb1, had several effects on HAM/TSP patients. First, no patients showed any dose-related toxicity and manifested progressive disease during the period of therapy. Two subjects (dosed at 0.5 mg/kg) and one subject (dosed at 1.0mg/kg) developed DVT after the protocol-specified observation period. Although it was not clear whether it was directly related to the treatment, prophylactic anticoagulation therapy was recommended as well as excluding patients that were nonambulatory. Hu-Mikb1 administered at 3-week intervals achieved greater than 90% saturation of CD122 on NK cells and CD8 + T cells in five of nine HAM/TSP patients. Saturation of CD122 by Hu-Mikb1 was more consistently observed among patients receiving the higher doses of Hu-Mikb1. The results would be consistent with the first phase I clinical trial of Hu-Mikb1 in patients with T cell large granular lymphocyte leukemia. 21 Among the five HAM/TSP patients that demonstrated CD122 saturation, three patients demonstrated sustained saturation of CD122 on NK cells and CD8 + T cells during the HuMikb1 treatment period and then lost saturation of CD122 by 6 weeks after the final dose. Importantly, the higher doses of Hu-Mikb1 administration provided more inhibitory effects on activated T cell functions of HAM/ TSP patients, which are the characteristic features of T cell dysregulation in HAM/TSP patients. 19, 20, 22, 28 In addition, HAM/TSP patients with longer disease duration (such as HAM#5, #6, and #8) seemed to show more effects of Hu-Mikb1 on CD122 saturation and inhibition of activated CD8 + T cells compared to HAM/TSP patients with shorter disease duration (such as HAM#7), which might be related to chronic activation and/or expansion of CD8 + T cells in the patients. It has been previously reported that Hu-Mikb1 was able to inhibit the activated T cell functions in ex vivo experiments using PBMCs of HAM/TSP patients. 19, 20, 22 In the current study, our results strongly supported the inhibitory effects of HuMikb1 on activated T cell functions of HAM/TSP patients in vivo, suggesting that Hu-Mikb1 would effectively inhibit IL-15-driven T cell dysfunction of HAM/TSP patients when IL-2/IL-15Rb saturation is achieved.
Chronic viral infection has been reported to induce expression of inhibitory molecules that generate negative signals to downregulate the ensuing T cell responses. Expression of multiple distinct inhibitory receptors is associated with greater T cell exhaustion and rapid disease progression. 36 In our cohort, higher frequencies of PD-1 We also demonstrated that higher frequency of Tscm cells was detected in CD8 + T cells of HAM/TSP patients compared to HVs. Tscm cells have similar functions to memory T cells including the ability to proliferate rapidly and release inflammatory cytokines in response to antigen reexposure, and a dependence on IL-15 and IL-7 for homeostatic turnover. 33, 34 To achieve long-lived protection against chronic HTLV-1 infection, an adequate number of functionally competent memory CD8 + T cells might be sustained through cytokine-driven homeostatic proliferation. Recently, it has been reported that frequency of CD8 + Tscm cells was increased in patients with acquired aplastic anemia and uveitis, immune-mediated diseases associated with autoreactive cytotoxic CD8 + T cells. 35, 37 Intriguingly, Tscm cells in CD4 + T cells have been able to sustain themselves through a process of selfrenewal and to reconstitute the identical adult T cell leukemia clones. 38 Although there were no significant changes in the frequency of CD244 
